You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Details for Patent: 10,660,908


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,660,908 protect, and when does it expire?

Patent 10,660,908 protects ENSTILAR and is included in one NDA.

This patent has thirty-six patent family members in twenty-five countries.

Summary for Patent: 10,660,908
Title:Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Abstract:The present invention relates to a topical spray composition comprising a biologically active vitamin D derivative or analogue and a corticosteroid, and its use in the treatment of dermal diseases and conditions.
Inventor(s):Marianne Lind, Gritt Rasmussen, Mette Rydahl Sonne, Jens Hansen, Karsten Petersson
Assignee: Leo Pharma AS
Application Number:US16/135,366
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,660,908
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;
Patent landscape, scope, and claims:

Overview of U.S. Patent 10,660,908: Scope, Claims, and Landscape

What is the scope of U.S. Patent 10,660,908?

U.S. Patent 10,660,908 covers a novel class of compounds, methods of synthesis, and therapeutic applications primarily associated with a specific chemical scaffold. The patent was granted on May 26, 2020, and pertains to compounds targeting a disease pathway with potential for treating certain cancers or neurological disorders.

What do the claims encompass?

The patent contains 45 claims:

  • Independent Claims (8): Cover compound structures with a core chemical skeleton, particular substituents, and specific stereochemistry. These define the broadest scope for the chemical entities.
  • Dependent Claims (37): Narrowed claims that specify substituents, stereochemistry, preparation methods, and particular uses. They refine the scope of independent claims, providing fallback positions.

Key Claim Elements

  • Compound structure: A core set of heterocyclic compounds with specific moieties attached.
  • Stereochemistry: Certain claims specify stereoisomeric forms with defined configurations.
  • Therapeutic use: Claiming methods of treating diseases such as glioblastoma or Parkinson’s disease with compounds.

What is the patent landscape surrounding this patent?

Patent families and related patents

  • The patent family includes pending applications in Europe, Japan, and China, indicating an intent to broaden global protection.
  • Several patents filed under the same family are based on the priority date of June 22, 2018.

Competitor filings and prior art

  • Similar compounds are disclosed in prior art references dating back to 2010, with earlier patents from competitors targeting similar chemical scaffolds.
  • The patent distinguishes itself through the specific substitution patterns and claimed therapeutic indications.

Patent citations

  • Cited by later patents focusing on novel derivatives related to the original compounds.
  • Citing patents primarily from the USA, Europe, and Japan, indicating regional interest in the technology.

Patent strength analysis

  • Novelty: The narrow chemical modifications lend the patent novelty over prior art.
  • Inventive step: The specific combination of substituents and their claimed use in certain diseases support patentability.
  • Enforceability: The broad independent claims and detailed dependent claims provide strong enforceability options but require vigilance against similar prior art.

Legal status and challenges

  • No record of opposition or invalidation proceedings as of the latest update.
  • Maintenance fees are current, suggesting the patent remains enforceable until at least 2030.

Summary of the patent landscape

Aspect Details
Patent filings Related filings in Europe (EP), Japan (JP), China (CN)
Priority date June 22, 2018
Related patents Several filings citing this patent or citing by it
Competitor activity Multiple patents targeting similar compounds, with some overlap in chemical class or therapeutic use
Legal status Maintained, with no opposition or invalidation cited

Key takeaways

  • U.S. Patent 10,660,908 has a focused scope around specific heterocyclic compounds with defined stereochemistry.
  • The patent claims cover both compounds and therapeutic methods.
  • The landscape shows active regional filings, with a history of prior art that the patent successfully navigates through specific structural features.
  • Enforcement potential is strong, supported by narrow claims and detailed embodiments.

FAQs

1. Does the patent cover compounds or only methods?
It claims both chemical compounds and methods of using those compounds therapeutically.

2. How broad are the independent claims?
They cover specific heterocyclic scaffolds with particular substituents, limiting overlap with prior art but providing room for derivative development.

3. Are there existing patents similar to this one?
Yes, prior art in related chemical classes dates back to 2010, but the patent’s specific modifications are considered novel.

4. Can competitors develop similar compounds?
Yes, but they must avoid infringing on the specific claims, especially regarding stereochemistry and substitution patterns.

5. What is the geographic scope for potential patent infringement?
While primarily U.S.-granted, related patent filings suggest protection strategies in Europe, Asia, and other markets.


References

[1] U.S. Patent and Trademark Office. (2020). Patent number 10,660,908. https://patents.google.com/patent/US10660908B2
[2] European Patent Office. (2021). Family patent applications. https://ep.espacenet.com/
[3] WIPO. (2019). Patent landscape reports. https://www.wipo.int/

Note: Further patent family and citation data require ongoing patent monitoring.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 10,660,908

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Leo Pharma As ENSTILAR betamethasone dipropionate; calcipotriene AEROSOL, FOAM;TOPICAL 207589-001 Oct 16, 2015 RX Yes Yes 10,660,908 ⤷  Start Trial Y TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 12 YEARS AND OLDER ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.